Cargando…

Nanocarriers for anticancer drugs: Challenges and perspectives

Cancer is the second most common cause of death globally, surpassed only by cardiovascular disease. One of the hallmarks of cancer is uncontrolled cell division and resistance to cell death. Multiple approaches have been developed to tackle this disease, including surgery, radiotherapy and chemother...

Descripción completa

Detalles Bibliográficos
Autor principal: Alqosaibi, Amany I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130109/
https://www.ncbi.nlm.nih.gov/pubmed/35645591
http://dx.doi.org/10.1016/j.sjbs.2022.103298
_version_ 1784712917007990784
author Alqosaibi, Amany I.
author_facet Alqosaibi, Amany I.
author_sort Alqosaibi, Amany I.
collection PubMed
description Cancer is the second most common cause of death globally, surpassed only by cardiovascular disease. One of the hallmarks of cancer is uncontrolled cell division and resistance to cell death. Multiple approaches have been developed to tackle this disease, including surgery, radiotherapy and chemotherapy. Although chemotherapy is used primarily to control cell division and induce cell death, some cancer cells are able to resist apoptosis and develop tolerance to these drugs. The side effects of chemotherapy are often overwhelming, and patients can experience more adverse effects than benefits. Furthermore, the bioavailability and stability of drugs used for chemotherapy are crucial issues that must be addressed, and there is therefore a high demand for a reliable delivery system that ensures fast and accurate targeting of treatment. In this review, we discuss the different types of nanocarriers, their properties and recent advances in formulations, with respect to relevant advantages and disadvantages of each.
format Online
Article
Text
id pubmed-9130109
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91301092022-05-26 Nanocarriers for anticancer drugs: Challenges and perspectives Alqosaibi, Amany I. Saudi J Biol Sci Review Cancer is the second most common cause of death globally, surpassed only by cardiovascular disease. One of the hallmarks of cancer is uncontrolled cell division and resistance to cell death. Multiple approaches have been developed to tackle this disease, including surgery, radiotherapy and chemotherapy. Although chemotherapy is used primarily to control cell division and induce cell death, some cancer cells are able to resist apoptosis and develop tolerance to these drugs. The side effects of chemotherapy are often overwhelming, and patients can experience more adverse effects than benefits. Furthermore, the bioavailability and stability of drugs used for chemotherapy are crucial issues that must be addressed, and there is therefore a high demand for a reliable delivery system that ensures fast and accurate targeting of treatment. In this review, we discuss the different types of nanocarriers, their properties and recent advances in formulations, with respect to relevant advantages and disadvantages of each. Elsevier 2022-06 2022-04-22 /pmc/articles/PMC9130109/ /pubmed/35645591 http://dx.doi.org/10.1016/j.sjbs.2022.103298 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Alqosaibi, Amany I.
Nanocarriers for anticancer drugs: Challenges and perspectives
title Nanocarriers for anticancer drugs: Challenges and perspectives
title_full Nanocarriers for anticancer drugs: Challenges and perspectives
title_fullStr Nanocarriers for anticancer drugs: Challenges and perspectives
title_full_unstemmed Nanocarriers for anticancer drugs: Challenges and perspectives
title_short Nanocarriers for anticancer drugs: Challenges and perspectives
title_sort nanocarriers for anticancer drugs: challenges and perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130109/
https://www.ncbi.nlm.nih.gov/pubmed/35645591
http://dx.doi.org/10.1016/j.sjbs.2022.103298
work_keys_str_mv AT alqosaibiamanyi nanocarriersforanticancerdrugschallengesandperspectives